



helping restore our
WAY OF LIFE

November 2021

CSE: HUGF
NASDAQ: HUGF
FRA: 0K9A

FSD Pharma Inc. Disclaimer

IMPORTANT: You Must Read The Following Before Continuing

The information contained in this presentation has been prepared by FSD Pharma Inc. (“FSD” or “the Company”) and contains information pertaining to the business, operations, assets and prospects of the Company. The information contained in this presentation (a) is provided as at the date hereof, unless otherwise stated, and is subject to change without notice, (b) does not purport to contain all the information that may be necessary or desirable to fully and accurately evaluate an investment in the Company, and (c) is not to be considered as a recommendation by the Company that any person make an investment in FSD. Other than as may be required by applicable laws, the Company is under no obligation to update any information included in this presentation. An investment in the securities of the Company is speculative and involves a number of risks. Other than as may be authorized by the Company upon request, this presentation may not be reproduced, in whole or in part, in any form or forwarded or further distributed to any other person. Any forwarding, distribution or reproduction of this presentation in whole or in part is unauthorized. The Company takes no responsibility for, and provides no assurance as to the reliability of, any information that others may give readers of this presentation.

All references to \$ or “dollar” in this presentation are references to USD, unless otherwise indicated.

Forward-Looking Statements

This document contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only FSD’s beliefs and assumptions regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of FSD’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “target”, “objectives”, “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, “potential” or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. The forward-looking information and forward-looking statements contained herein may include, but are not limited to, expectations regarding the timing and results of the Company’s focus on the development of its drug candidates. This forward-looking information is based on certain assumptions made by management and other factors used by management in developing such information. Although FSD believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking

information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. Risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, as applicable, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information and statements include, among others: risks and uncertainties related to the recent outbreak of COVID-19 and the impact it may have on the global economy, risks and uncertainties related to drug development, the ability to raise sufficient capital to advance the business of the Company and to fund planned operating and capital expenditures and acquisitions; achieving the anticipated results of the Company’s strategic plans; the Company’s limited operating history; inability to effectively manage growth; and increasing competition in the industry. The forward-looking information and forward-looking statements contained in this presentation are made as of the date of this presentation, and FSD does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to FSD or persons acting on its behalf are expressly qualified in its entirety by this notice.

Pipeline of Clinical Candidates Addressing Multibillion-Dollar Markets

FSD Pharma is focused on innovative biotech space to bring advanced neurodegenerative, inflammatory and mental health treatments to market. We are rooted in world-class science and research-based advancements.

1

Lucid-PSYCH

A psychoactive molecule for the treatment of neuropsychiatric disorders currently undergoing IND-enabling studies

2

Lucid-MS

A patented neuroprotective NCE shown to prevent and reverse myelin degradation, the underlying cause of multiple sclerosis, in preclinical models. Currently undergoing IND enabling studies

3

FSD-PEA

A proprietary anti-inflammatory product completed phase-1 clinical trials with excellent safety profile, and is under evaluation for a suitable indication to launch phase-2 clinical trials

Expert Research and Clinical Team



Lakshmi P. Kotra, BPharm(Hons), PhD
CEO of Lucid

- Professor, Leslie Dan Faculty of Pharmacy, University of Toronto
- Senior Scientist, Kemble Research Institute, University Health Network
- Expert in drug discovery and development
- Serial entrepreneur and co-founder of multiple companies
- R&D and Operations lead



Hance A. Clarke, PhD, FRCPC(C)
Research & Clinical Advisory Board

- Director, TGH Pain Clinic
- Key Opinion Leader in Anesthesiology and CNS Acting Agents



Shannon Dunn, PhD
Research & Clinical Advisory Board

- Senior Scientist, St. Michael's Hospital
- Immunology and neurodegenerative diseases



Eleanor Fish, PhD
Research & Clinical Advisory Board

- Professor and Associate Chair, Dept Immunology, Univ of Toronto
- Immunology and Inflammatory disorders



Peter K. Stys, MD, FRCPC(C), FRSC
Research & Clinical Advisory Board


- Hotchkiss Brain Institute, University of Calgary
- Neurodegenerative diseases



Albert H.C. Wong, MD, PhD, FRCPC(C)
Research & Clinical Advisory Board

- Psychiatrist, Center for Addiction and Mental Health
- Depression, PTSD, Schizophrenia, Bipolar disorder

Clinical and Research Advisory Board



Daniele Piomelli, PhD, MD
Research & Clinical Advisory Board

- Professor, University of California at Irvine
 - Leading expert in endocannabinoids and associated treatments
 - Chief Editor, Cannabis and Cannabinoids Research
-

Regulatory Advisory Board



Joga Gobburu, PhD, MBA

- Professor of Pharmacometrics, Univ of Maryland at Baltimore
 - Ex-US FDA Official with significant regulatory expertise
-

Mary Melnyk, PhD

- Global Regulatory expertise in small molecules development
 - Large pharma experience, for all phases of development
-

Kwok Chow, PhD

- President, Covar Pharma – a CDMO with global drug development expertise
 - Regulatory strategies coupled of product development
-




The Psychedelics Market Opportunity (Lucid-PSYCH)

Growing body of research suggests Psychedelics have the potential to treat a variety of neuropsychiatric disorders such as PTSD, depression, specifically complex TRD and MDD, and anxiety

- FDA approval of SPRAVATO® (esketamine) for treatment-resistant depression
- Promising Ph2 clinical data on MDMA-assisted psychotherapy for PTSD treatment
- Expanding pipeline of psychedelic-based therapies

Millions of people suffer from mental illness each year; representing a multi-billion dollar opportunity

FSD sees a significant opportunity in becoming an early mover in developing psychedelic assets



Source: Canaccord Around the Corner May 2020



Major Depressive Disorder (MDD) (Lucid-PSYCH)

MDD Overview

- Characterized by depressed mood or loss of interest in pleasure for at least 2 weeks
- Periods of remission and relapse over a lifetime
- 300 million people worldwide living with depression²
 - 10% of Canadians will experience MDD at some point in their life³
 - 13 million adults with MDD in the U.S.
 - 3% incidence rate globally
- Economic burden in U.S. of \$210 billion annually
- First line treatment is antidepressants with or without psychotherapy

The global anxiety disorders and depression treatment market size was valued at **US\$15.2B** in 2015¹

Psychedelics market for mental illness: **CAGR of 16.3%** during 2020–27 and expected to reach **US\$6.9 Billion** by 2027 from \$2.0 Billion in 2019⁴

1) <https://www.grandviewresearch.com/industry-analysis/anxiety-disorders-and-depression-treatment-market>*


2) <https://www.who.int/news-room/fact-sheets/detail/depression>

3) <https://www.walkalong.ca/explore/encyclopedia/major-depressive-disorder-depression>

4) <https://www.prnewswire.com/news-releases/psychedelic-drugs-market-projected-to-reach-6-859-95-million-by-2027--301069861.html> and Data Bridge Market Research



FSD Pharma Differentiation (Lucid-PSYCH)



Source: Psilocybin with Psychological Support for Treatment Resistant Depression, R. Carhart-Harris, The Lancet

	Lucid-PSYCH
Development Stage	Preclinical
Target Condition	Mental health and neurodegenerative conditions
Proprietary molecules	Yes
Time to Market	5-8 years
IP/Innovation	Yes
Market Access Strategy	Multiple entry points




Multiple Sclerosis (Lucid-MS)

MS Overview¹

- A chronic inflammatory and degenerative disorder of the central nervous system
- Unpredictable pattern of symptoms (tingling, vision problems, mobility issues, etc.) has to do with which nerves a patient's immune system attacks at any given time
- The damage MS does to nerves can also affect critical thinking and other cognitive (mental) skills
- Effects approx. 2.5 million worldwide (1 million of which are in the U.S.)
 - Female to male ratio ~ 2:1
 - Prevalence ~ 1/1,000

Current treatment market valued at **US\$23B** globally²

1. <https://www.healthline.com/health/multiple-sclerosis/facts-you-should-know#varied-symptoms>
2. <https://www.globenewswire.com/fr/news-release/2021/01/19/2160432/0/en/Clene-Nanomedicine-Receives-Patent-Notice-of-Allowance-in-the-United-States-for-using-Gold-Nanocrystals-for-the-Treatment-of-Multiple-Sclerosis.html>




Source: Lancet Neurol. 2019 Mar; 18(3):269-285




Lucid-MS: Disease Modifying Agent Enabling Remyelination


Myelin (Neuronal Insulator) is Attacked
by MS Patients' Immune System



Demyelination



Goal = Remyelination





Lucid-MS: Disease Modifying Agent Enabling Remyelination


- Lucid-MS has over 11 years of R&D and FSD owns worldwide exclusive rights for the family of compounds for development and marketing
- Excellent efficacy in various preclinical animal models
- Treatment accelerates functional recovery of diseased mice, preserved myelin, and reduced axonal degeneration
- Does not suppress immune system (non-immunomodulatory)
- Potential oral administration with easy dosing regimen
- Currently preclinical development with anticipated IND in the Fall, 2022



FSD-PEA: Ultra Micro-PEA

An anti-inflammatory agent

- A well-researched compound in preclinical and clinical studies
- Addresses large markets with growth opportunities in opioid-sparing indications (pain, post-surgical pain, morphine tolerance etc.), endometriosis, osteoarthritis, fibromyalgia etc.
- An endogenous molecule as an API, a growing trend in inflammatory and related therapeutics



Proposed mechanism of action of PEA with red lines indicating canonical signaling, black lines as strongly supported, and grey as hypothesized (The Basal Pharmacology of Palmitoylethanolamide)



Int'l. J. Mol. Sci. (2020) 21(21):7942.



FSD-PEA: Ultra Micro-PEA

An anti-inflammatory agent

- An endogenous compound, and a key regulator of endocannabinoid system in inflammation
- PEA activates GPR55 and PPAR- α receptors, leads to increased expression of CB2 receptors
- PEA increases the endogenous levels of 2-AG and AEA, which directly activate CB1, CB2, and TRPV1 receptors
- PEA inhibits the activation of mast cells (peripheral)
- PEA reduces the activation of microglia and astrocytes (CNS)
- Clinical data available that suggests that FSD-PEA is superior to Pregabalin, Duloxetine, Ibuprofen and the opiates in the treatment of pain







FSD-PEA: Ultra Micro-PEA

An anti-inflammatory agent

- FSD-PEA is a proprietary formulation, enhances its bioavailability and efficacy
- FSD Holds exclusive worldwide licensing rights (except Italy & Spain) to FSD-PEA
- Successfully completed Phase-1 first-in-human safety and tolerability trial
- FSD-PEA following single dose ranging from 600 mg - 2400 mg *p.o.* and multiple doses ranging from 600 mg – 2,000 mg *p.o., b.i.d.* were safe and well-tolerated in normal healthy subjects
- Potential target indications for Phase 2 trials are being analyzed



Pipeline



Comparable Companies with Similar Drug Candidate Targets

	Company	Symbol	Market Cap*	Psychedelics	Multiple Sclerosis	PEA
Atai Life Sciences	 atai LIFE SCIENCES	ATAI	\$2.1B	✓		
COMPASS Pathways	 COMPASSION Navigating Mental Health Pathways	CMPS	\$1.25B	✓		
Eliem Therapeutics	 eliem Therapeutics	ELYM	\$520.1M			✓
MediciNova	 MEDICINOVA	MNOV	\$179.7M		✓	
Longboard Pharmaceuticals	 LONGBOARD PHARMACEUTICALS	LBPH	\$155.8M		✓	
FSD Pharma	 FSD PHARMA	HUGE	\$59.6M	✓	✓	✓

* As of 10/4/2021

Experienced Executive Leadership Management Team



Anthony Durkacz
Executive Co-Chairman,
Co-Founder & Interim CEO



Nathan Coyle, CPA
Chief Financial Officer



Zeeshan Saeed
Executive Co-Chairman,
Co-Founder & President



Lakshmi Kotra, PhD
CEO of Lucid



Donal Carroll
Director

Board of Directors

Anthony Durkacz

Zeeshan Saeed

Donal Carroll

Larry Latowski

Adnan Bashir

Fernando Cugliari

Nitin Kaushal

Investment Highlights

Focused on Advancing Neuro and Anti-inflammatory Assets

- Lucid-PSYCH
- Lucid-MS
- FSD-PEA

Positioned for Growth

Strategically advancing drug pipeline focused on novel and unique treatments – unmet needs and large growing markets

Well-Capitalized

Ability to pursue and integrate acquisitions that present compelling opportunities across the psychedelics and innovative biotech space focused on the pursuit of total brain health

Contacts

Investor Relations

Stephen Kilmer

Email: skilmer@fsdpharma.com

Corporate

Anthony Durkacz

Interim CEO

Email: adurkacz@fsdpharma.com

Zeeshan Saeed

*Founder, President and
Executive Co-Chairman*

Email: zsaeed@fsdpharma.com

www.fsdpharma.com

